Skip to main content
. Author manuscript; available in PMC: 2010 Jul 16.
Published in final edited form as: Clin Adv Hematol Oncol. 2009 Jan;7(1):54–64.

Table 5.

Aurora and Polo-like Kinases in Clinical Evaluation

Target Agent Phase of
Development		 DLT and/or AE* Clinical Results† Ref.
Aurora
Kinase		 VX-680
(A,B,C
inhibitor)		 II Neutropenia 19% SD 89, 90
AZD1152
(B only
inhibitor)		 I/II Neutropenia 38% SD 91
Polo-like
kinase 1
(PLK1)		 BI 2536 II Neutropenia,
thrombocytopenia		 1 PR: mSCHNC‡ 97, 98
ON
01910.Na		 I Anemia,
leukopenia,
transaminitis, GI
symptoms, fatigue		 Ongoing 99, 100
*

DLT dose-limiting toxicity, AE adverse events

†

SD stable disease, PR partial response

‡

mSCHNC metastatic squamous cell head and neck cancer